A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for advanced pancreatic cancer
Histologically and/or cytologically proven locally advanced or metastatic pancreatic adenocarcinoma
Patients must have i) received at least one line of chemotherapy OR ii) are medically unfit for further chemotherapy, AND iii) the tumor is still not deemed as resectable with radical surgery or the patient does not wish to go through surgery
Target lesion is technically amenable for at least 50% coverage by the Alpha DaRT seeds as determined by the treating physician
Interstitial radiation indication validated by a multidisciplinary team
Concomitant chemotherapy or immunotherapy within the past 4 weeks
Brain metastases
Borderline unresectable pancreatic cancer, and/or cases fit for surgical exploration unless patient refuses surgery
Known hypersensitivity to any of the components of the treatment.
Alpha Tau Medical LTD.
Lead sponsor